CEO Ivor Elrifi Adds $319K in Tiziana Shares, Total Stake Reaches 4.79M
TLSA is trading near its 52-week low of $0.866 (14% above the low) on elevated volume (3.3× avg).
Summary
Tiziana Life Sciences CEO Ivor Elrifi purchased an additional 321,423 shares for $318,909, following a $667,000 buy two days earlier. His total stake now exceeds 4.79 million shares.
Key Events · Ownership and Investor Activity · TLSA
-
CEO Adds $319K in Shares
Ivor Elrifi acquired 321,423 shares at $0.97–$1.00, a $318,909 investment, increasing his total holdings to 4,793,684 shares.
-
Rapid Accumulation Pattern
This purchase follows a $667,000 buy on August 4, bringing his two-day total to nearly $986,000 in open-market purchases.
-
Clinical Momentum Backdrop
The purchases come after positive Phase 2 data for intranasal foralumab in multiple system atrophy, including a 34% reduction in neuroinflammation in the third patient.
-
Insider Conviction Signal
As CEO, Elrifi's back-to-back open-market buys at around $1.00 per share demonstrate strong belief in the company's near-term prospects.
Analysis · TLSA · Life Sciences
CEO Ivor Elrifi bought another 321,423 shares at $0.97–$1.00, investing $318,909 just days after a $667,000 purchase. His total holdings now stand at 4.79 million shares. This second rapid accumulation by the chief executive, coming on the heels of positive Phase 2 foralumab data, signals strong personal conviction in the company's clinical trajectory.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLSA was trading at $0.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $127M. The 52-week trading range was $0.87 to $2.53. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.